Welcome to our dedicated page for Supernus Pharmaceuticals news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharmaceuticals stock.
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is a leading specialty pharmaceutical company dedicated to developing and commercializing innovative products for the treatment of central nervous system (CNS) disorders. With over two decades of experience in the industry, Supernus has made significant strides in neurology and psychiatry.
Supernus’ product portfolio is diverse, including approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. Flagship products include Trokendi XR®, Oxtellar XR®, Qelbree®, APOKYN®, XADAGO®, MYOBLOC®, GOCOVRI®, and Osmolex ER®.
In 2013, Supernus successfully launched two groundbreaking products: Oxtellar XR® and Trokendi XR®, both aimed at treating epilepsy. These innovative formulations offer extended-release solutions, enhancing patient convenience and compliance.
Beyond these milestones, Supernus is actively developing new therapeutic candidates in psychiatry to address unmet medical needs in ADHD, depression, and their co-existing disorders. The company leverages proprietary and in-licensed technologies to create differentiated products. By focusing on known drug compounds with established mechanisms of action, Supernus minimizes the risks, costs, and time associated with new drug development.
Supernus has recently announced notable developments:
- Financial and business results for Q4 and the full year of 2023 will be reported on February 27, 2024.
- Actress Busy Philipps has partnered with Supernus to raise awareness about ADHD during Mental Health Awareness Month, spotlighting Qelbree® as a non-stimulant medication for ADHD.
- Supernus signed an exclusive licensing agreement with M8 Pharmaceuticals to commercialize Qelbree® in Latin America, expanding its reach and impact.
With a strong foundation and ongoing projects, Supernus Pharmaceuticals continues to make significant contributions to the field of CNS disorders, enhancing patient lives through innovative solutions.
Supernus Pharmaceuticals has completed its acquisition of Adamas Pharmaceuticals, enhancing its Parkinson’s disease portfolio with GOCOVRI® and Osmolex ER®. The deal diversifies revenue streams, expected to yield synergies of $60M to $80M in the first year, and is projected to be accretive in 2022. Supernus offered $8.10 cash per share of Adamas, totaling about 77.3% tendered shares. Adamas stock will be delisted post-merger. The acquisition aligns with Supernus's strategy to strengthen its CNS product offerings, contributing to cash flow stability.
Supernus Pharmaceuticals (NASDAQ: SUPN) announced that the waiting period under the Hart-Scott-Rodino Act for its proposed acquisition of Adamas Pharmaceuticals (NASDAQ: ADMS) expired on November 22, 2021. The acquisition offer includes $8.10 per share in cash and two contingent value rights (CVRs) worth up to $1.00, dependent on achieving sales milestones by December 2024 and December 2025. The tender offer expires at 11:59 p.m. on November 23, 2021, unless extended. Upon completion, Adamas will become a wholly-owned subsidiary of Supernus.
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) announced participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. Management will hold a fireside chat available from 10:00 a.m. ET on November 22, 2021, with an archived replay accessible for 60 days. Supernus focuses on developing treatments for central nervous system diseases, including epilepsy and Parkinson’s disease. The company will also host investor meetings on December 1, 2021.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced its participation in two investor conferences in November 2021. The Stifel 2021 Virtual Healthcare Conference is scheduled for November 15 at 2:00 p.m. EST, featuring a fireside chat format. The Jefferies London Healthcare Conference will take place on November 18, with a pre-recorded session available from 3:00 a.m. EST / 8:00 a.m. GMT. Live webcasts and archived replays of both chats will be accessible on the company’s website for 60 days post-conference.
Supernus Pharmaceuticals reported a 12% increase in total revenues for the first nine months of 2021, reaching $420.7 million compared to $376.8 million in 2020. However, Q3 revenues decreased by 4% to $148.5 million year-over-year. The company is diversifying its Parkinson's portfolio through the proposed $450 million acquisition of Adamas Pharmaceuticals, aiming to enhance revenue and cash flow. Key product Qelbree saw accelerated growth, with a significant rise in prescriptions. Financial guidance for 2021 reflects an increase in operating earnings, with total revenue expected between $550 million and $570 million.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that it will report its third quarter 2021 financial results on November 3, 2021, after market close. The company's President and CEO, Jack Khattar, along with SVP and CFO Tim Dec, will host a conference call at 4:30 p.m. ET to discuss the results and address questions. A live webcast will be accessible on their website, with a recording available for 60 days thereafter. Supernus specializes in CNS disease treatments, including epilepsy and ADHD, and is developing new potential therapies.
Holly Robinson Peete and her daughter Ryan are collaborating with Supernus Pharmaceuticals to enhance awareness about Attention-deficit/Hyperactivity Disorder (ADHD) during ADHD Awareness Month. With ADHD affecting 6.1 million U.S. children, Peete aims to reduce stigma and promote understanding of the condition. Supernus Pharmaceuticals supports this initiative, emphasizing the importance of recognizing ADHD's symptoms and encouraging families to seek treatment. The partnership offers resources at MoreToADHD.com for those affected by the disorder.
Supernus Pharmaceuticals announced its agreement to acquire Adamas Pharmaceuticals for $8.10 per share in cash, totaling approximately $400 million. The deal includes contingent value rights that could raise the total to $9.10 per share, based on sales milestones of GOCOVRI. This acquisition is strategically significant as it strengthens Supernus's Parkinson's disease portfolio with two FDA-approved products, GOCOVRI and Osmolex ER, and is expected to generate $60 million to $80 million in synergies in the first year. The transaction is projected to close in Q4 2021 or Q1 2022.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that the FDA has accepted its supplemental new drug application for Qelbree (viloxazine extended-release capsules) aimed at treating ADHD in adults. The sNDA's user fee goal date is set for April 29, 2022. A Phase III study previously showed significant efficacy and tolerability of Qelbree in adult patients. Qelbree, already approved for pediatric use, represents a new treatment option for approximately 10 million adults with ADHD in the U.S., according to CEO Jack Khattar.
Supernus Pharmaceuticals, focused on CNS disease treatments, will participate in three key virtual investor conferences in September 2021.
- Citi’s 16th Annual BioPharma Virtual Conference: September 9, 2021, one-on-one meetings.
- Wells Fargo 2021 Virtual Healthcare Conference: September 10, 2021, presentation at 9:20 a.m. ET.
- Morgan Stanley 19th Annual Global Healthcare Conference: September 15, 2021, fireside chat at 11:45 a.m. ET.
Webcasts available on their website post-conference.
FAQ
What is the current stock price of Supernus Pharmaceuticals (SUPN)?
What is the market cap of Supernus Pharmaceuticals (SUPN)?
What types of disorders does Supernus Pharmaceuticals focus on?
What are some of the key products developed by Supernus Pharmaceuticals?
What recent collaborations has Supernus Pharmaceuticals announced?
When will Supernus Pharmaceuticals report its financial results for Q4 and the full year of 2023?
What is the significance of Qelbree®?
How does Supernus Pharmaceuticals leverage its proprietary technologies?
What is the main focus of Supernus Pharmaceuticals' ongoing projects?
Who are the key executives at Supernus Pharmaceuticals?
What are the safety concerns related to Qelbree®?
Where can I find more information about Supernus Pharmaceuticals and its products?
